Incanthera Plc · AQUIS:INC
Incanthera — Life Sciences Forum 2021
14 slides from Incanthera's conference presentation, Sep 23, 2021
Slide 1: Innovative Technologies for Oncology and Dermatology
Innovative Technologies for Oncology and Dermatology Life Sciences Forum 23 September 2021
Slide 2: Disclaimer
Innovative Technologies for Oncology and Dermatology Disclaimer The information contained in these slides and any accompanying verbal presentation, any question and answer session and any document or material distributed at or in connection with the verbal presentation (together, the “Presentation”)
Slide 3: Novel Cancer Medicines through Targeted Technology
Oncology Novel Cancer Medicines through Targeted Technology Acquire, Prepare, Commercialise 3
Slide 4: Company Heritage
Innovative Technologies for Oncology and Dermatology Company Heritage Incanthera was established as a UK oncology focused, targeted drug development company originating from the Institute of Cancer Therapeutics, University of Bradford (UoB) Acquiring, preparing and commercialising new oncology techn
Slide 5: Our Approach
Innovative Technologies for Oncology and Dermatology Our Approach Identify cutting Acquire intellectual Prepare Commercialise through a partner, edge technologies property rights technologies securing deal that aims to prioritise in oncology and to product to valuation further development, marketing
Slide 6: The Incanthera Team
Innovative Technologies for Oncology and Dermatology The IncantheraTeam Tim McCarthy Simon Ward Alan Warrander Pawel Zolniercyk Laura Brogden Suzanne Brocks Corporate & City Technology & Industry & Licensing IP & Tech- Transfer Financial Control Shareholders, Chairman (Board) Development NED (Board)
Slide 7: Growth since admission to AQSE
Innovative Technologies for Oncology and Dermatology Growth since admission to AQSE Month News February 2020 Admission to AQSE at debut price of 9.5p AQSE: INC July 2020 New Patent Filing for Sol Skin Cancer Technology September 2020 Successful Results of Permeation Study September 2020 Successful R
Slide 8: Oncology Product Pipeline
Innovative Technologies for Oncology and Dermatology Oncology Product Pipeline Programme Preparation for Licensing Licensing Platform Product Indication Skin cancers: solar keratosis Sol Topical Cream (SK), melanoma (SK - $3.4bn)* Bioequivalence Market Launch VDA & Lung, breast, ovarian cancers Ther
Slide 9: Focus: Sol and the Skin Cancer Challenge
Innovative Technologies for Oncology and Dermatology Focus: Sol and the Skin Cancer Challenge Skin cancer (including solar keratosis) is UK SKIN CANCER RATES 2004-2016 (NUMBERS PER 100,000) the most common form of cancer in white populations, and deaths arising from 30 invasive melanoma are on the i
Slide 10: Our Natural Defence
Innovative Technologies for Oncology and Dermatology Our Natural Defence GENOMIC STABILITY UV depletes ATP, reducing Cells have natural defence and cellular energy for DNA repair DNA repair capabilities, but this DNA DAMAGE DNA REPAIR SOL is compromised in skin cells by UV light UV IMMUNOSUPPRESSION
Slide 11: Sol – Opportunities and Advantages
Innovative Technologies for Oncology and Dermatology Sol – Opportunities and Advantages Advantages of Sol over oral dosing Opportunity – Sol A dermatological preparation • Avoidance of known possible • Direct targeting of sun exposed tissues and lesions of the natural agent to offer significant side
Slide 12: Sol Delivers
Innovative Technologies for Oncology and Dermatology Sol Delivers Two independent Proof of Principle Studies have demonstrated (Summer 2020): Amount of active moving across the skin Sol exceeds the The formulation Target to match bioequivalence test is non-irritant, oral dosing using human skin comp
Slide 13: Sol – Licensing
Innovative Technologies for Oncology and Dermatology Sol – Licensing Sol has been introduced to a selection of potential licensees These companies fall into two groups, being concerned either with cosmetics alone or pharmaceuticals (with or without cosmetics) Discussions with 2 global cosmetic compa
Slide 14: Investment Opportunity
Innovative Technologies for Oncology and Dermatology Investment Opportunity Progressing commercialisation discussions: Sol Differential Business Model Multiple product portfolio Established oncology pipeline Investor support through AQSE listing EIS/VCT qualified Acquire, Prepare, Commercialise 14